Trial Profile

An Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1/1b Study of IMU-201, a B-Cell Immunotherapy As Monotherapy or in Combination with Atezolizumab with or Without Chemotherapy, in Adults with Non- Small Cell Lung Cancer (IMPrinter)

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 11 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; IMU 201 (Primary) ; Antineoplastics; Montanide ISA-720
Indications Adenocarcinoma; Large cell carcinoma; Non-small cell lung cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Acronyms IMPRINTER
Sponsors Imugene

07 Nov 2024 Planned End Date changed from 1 Mar 2026 to 1 May 2025.
07 Nov 2024 Planned primary completion date changed from 1 Feb 2026 to 1 Nov 2024.
24 Jan 2024 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com